A carregar...
Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus
Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A...
Na minha lista:
| Publicado no: | FEBS Open Bio |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7530388/ https://ncbi.nlm.nih.gov/pubmed/32810922 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12956 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|